Status:
WITHDRAWN
Randomized Evaluation and Verification of Ventricular Enhancement
Lead Sponsor:
BioVentrix
Conditions:
Ischemic Cardiomyopathy
Heart Failure
Eligibility:
All Genders
Phase:
NA
Brief Summary
A prospective, multi-center, dual-arm randomized controlled study comparing treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC System plus Guideline Directed Medical Thera...
Detailed Description
The purpose of the study is to demonstrate that treatment with the BioVentrix Revivent TC System is more effective than guideline directed medical therapy for the treatment of ischemic heart failure. ...
Eligibility Criteria
Inclusion
- Patients suffering from heart failure symptoms with cardiac dysfunction caused by a previous myocardial infarction resulting in increased LV systolic volume and in a discrete, contiguous, acontractile, (akinetic and/or dyskinetic) scar located in the antero-septal, apical (may extend laterally) region of the left ventricle.
Exclusion
- Calcified ventricular wall in the area of intended scar exclusion as verified by one or more appropriate imaging modalities;
- Inadequate myocardial viability in regions remote from the scar.
- Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by echocardiography or equivalent that has not been adequately treated with weeks of anticoagulant at therapeutic levels;
- Cardiac Resynchronization Therapy (CRT) consisting of Bi-ventricular pacemaker device (i.e., not ICD only) placement ≤ 60 days prior to treatment;
- Patient intolerance or unwillingness to take anti-coagulation medication;
- Functioning pacemaker leads in antero-apical RV, which, in the opinion of the investigator, would interfere with anchor placement;
- Pulmonary Arterial Pressure \> 60 mm Hg shown by right heart catheterization to be precapillary or unresponsive to vasodilator therapy;
- Myocardial Infarction within 90 days prior to the procedure;
- Previous right neck surgery, previous pericardiotomy, previous left chest surgery that precludes device placement;
- Chronic renal failure with a serum creatinine \>2 mg/dL;
- Inoperable coronary disease with significant ischemia or pulmonary disease that would preclude transient single lung ventilation.
- Baseline 6-minute walk distance of \>450m
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03845127
Start Date
January 1 2020
End Date
December 31 2024
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
German Heart Institute Berlin and Charité University Medicine Berlin
Berlin, Germany, 13353